Skip to main content
. Author manuscript; available in PMC: 2023 Jan 1.
Published in final edited form as: Br J Haematol. 2021 Sep 27;196(1):169–178. doi: 10.1111/bjh.17840

Figure 1.

Figure 1.

(A) Overall Survival-OS in MRD/URD (Tacro/MTX), MRD/URD (PT/Cy), HRD (PT/Cy) recipients, as a function of years after transplant.

Hazard Ratios (HR): MRD/URD (Tacro/MTX) vs. MRD/URD (PT/Cy): HR= 0.723 (95% CI 0.161–3.251); MRD/URD (Tacro/MTX) vs. HRD (PT/Cy): HR= 0.258 (95% CI 0.029–2.313); MRD/URD (PT/Cy) vs. HRD (PT/Cy): HR= 0.372 (95% CI 0.038–3.596).

(B) Event Free Survival-EFS in MRD/URD (Tacro/MTX), MRD/URD (PT/Cy), HRD (PT/Cy) recipients, as a function of years after transplant.

Hazard Ratios (HR): MRD/URD (Tacro/MTX) vs. MRD/URD (PT/ Cy): HR= 0.940 (95% CI 0.234–3.785); MRD/URD (Tacro/MTX) vs. HRD (PT/Cy): HR = 0.547 (95% CI 0.100–2.985); MRD/URD (PT/Cy) vs. HRD (PT/Cy):HR= 0.590 (95% CI 0.108–3.233).